---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-284214"
form_type: "8-K"
ticker: "FULC"
cik: "0001680581"
company_name: "Fulcrum Therapeutics, Inc."
filed_at: "2024-12-23T23:59:59+00:00"
generated_at: "2026-05-28T23:39:09.572128+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# Sanofi terminates losmapimod deal; Fulcrum loses up to $975M in milestones

## Summary
- Sanofi terminated for convenience the May 2024 collaboration for losmapimod (FSHD) effective April 17, 2025.
- Fulcrum received $80M upfront but forfeits all remaining milestones (up to $975M) and tiered royalties.
- Fulcrum no longer entitled to global development cost reimbursement; Phase 3 trial obligations continue until termination.
- After termination, Fulcrum retains full rights to losmapimod but loses ex-U.S. partner and future payments.

## SEC filing metadata
- accession: 0001193125-24-284214
- form_type: 8-K
- ticker: FULC
- cik: 0001680581
- company_name: Fulcrum Therapeutics, Inc.
- filed_at: 2024-12-23T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 1.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1680581/000119312524284214/0001193125-24-284214-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1680581/000119312524284214/d911298d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-284214
- JSON: https://secwatch.observer/filing/0001193125-24-284214.json
- Plain text: https://secwatch.observer/filing/0001193125-24-284214.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.